158 related articles for article (PubMed ID: 22932705)
21. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
22. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
23. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
[TBL] [Abstract][Full Text] [Related]
24. Management of acute cardiac failure by intracoronary administration of levosimendan.
Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
[TBL] [Abstract][Full Text] [Related]
25. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
[TBL] [Abstract][Full Text] [Related]
26. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
[TBL] [Abstract][Full Text] [Related]
27. Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
Bocchi EA; Moura LZ; Issa VS; Cruz F; Carvalho VO; Guimarães GV
Cardiovasc Ther; 2013 Apr; 31(2):100-7. PubMed ID: 21884030
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
[TBL] [Abstract][Full Text] [Related]
29. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
[TBL] [Abstract][Full Text] [Related]
30. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
31. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure.
Ikonomidis I; Parissis JT; Paraskevaidis I; Kourea K; Bistola V; Lekakis J; Filippatos G; Kremastinos DT
Eur J Heart Fail; 2007 Dec; 9(12):1172-7. PubMed ID: 18062901
[TBL] [Abstract][Full Text] [Related]
32. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure.
Parissis JT; Karavidas A; Bistola V; Arapi S; Paraskevaidis IA; Farmakis D; Korres D; Filippatos G; Matsakas E; Kremastinos DT
Atherosclerosis; 2008 Mar; 197(1):278-82. PubMed ID: 17568589
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
Kolseth SM; Nordhaug DO; Stenseth R; Sellevold O; Kirkeby-Garstad I; Wahba A
Eur J Cardiothorac Surg; 2009 Dec; 36(6):1024-30. PubMed ID: 19592266
[TBL] [Abstract][Full Text] [Related]
34. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
35. Sustained hemodynamic effects of intravenous levosimendan.
Kivikko M; Lehtonen L; Colucci WS
Circulation; 2003 Jan; 107(1):81-6. PubMed ID: 12515747
[TBL] [Abstract][Full Text] [Related]
36. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
37. Intermittent levosimendan infusions in advanced heart failure: a real world experience.
Ortis B; Villani A; Oldani M; Giglio A; Ciambellotti F; Facchini M; Parati G; Malfatto G
J Int Med Res; 2017 Feb; 45(1):361-371. PubMed ID: 28222634
[TBL] [Abstract][Full Text] [Related]
38. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
[TBL] [Abstract][Full Text] [Related]
39. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
[TBL] [Abstract][Full Text] [Related]
40. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
